Characterization of a Robust Enzymatic Assay for Inhibitors of 2-Oxoglutarate-Dependent Hydroxylases
Kimon C. Kanelakis(Johnson & Johnson (United States)), Terrance D. Barrett(Janssen (United States)), Meghana V. Trivedi(University of Houston), Nigel P. Shankley(Johnson & Johnson (United States)), Jiejun Wu(Johnson & Johnson (United States)), Mark D. Rosen(Johnson & Johnson (United States)), Michèle Rizzolio(Johnson & Johnson (United States)), Lina Li(Hebei Medical University), Young Chul Yang(Johnson & Johnson (United States)), Wen Yan(Johnson & Johnson (United States)), Magda F. Morton(Johnson & Johnson (United States)), Michael H. Rabinowitz(Johnson & Johnson (United States)), Hariharan Venkatesan(Johnson & Johnson (United States)), Heather L. Palomino(Johnson & Johnson (United States))
Cited by 14
Related Papers
Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials
|The Lancet Diabetes & Endocrinology|2018|642
Metastasis Dormancy in Estrogen Receptor–Positive Breast Cancer
|Clinical Cancer Research|2013|273
Perspective on Circulating Tumor Cell Clusters: Why It Takes a Village to Metastasize
|Cancer Research|2018|221
Bidirectional Crosstalk between the Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 Signaling Pathways in Breast Cancer: Molecular Basis and Clinical Implications
|Breast Care|2013|200
FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer
|Proceedings of the National Academy of Sciences|2016|185